John Lewicki Biography and Net Worth

Insider of Mereo BioPharma Group

John joined Mereo as Chief Scientific Officer in July 2020. He has over 35 years of experience in the biotechnology industry.

John was President, CEO, and a board member of OncoMed Pharmaceuticals Inc. from March 2018 to April 2019. He joined as Senior Vice President of Research and Development in 2004 before assuming additional leadership roles.

Previously, John served as Vice President of Research, at Scios Inc where he co-discovered human B-type natriuretic peptide (BNP). John contributed to development of BNP into an FDA-approved treatment (Natrecor) for acute congestive heart failure.

John received his PhD from the University of California, San Diego. He has co-authored over 80 papers and is co-inventor on over 30 issued US patents.

What is John A. Lewicki's net worth?: The estimated net worth of John A. Lewicki is at least $182.72 thousand as of September 12th, 2024. Lewicki owns 89,567 shares of Mereo BioPharma Group stock worth more than $182,717 as of December 5th. This net worth approximation does not reflect any other assets that Lewicki may own. Learn More about John A. Lewicki's net worth.
How old is John A. Lewicki?: Lewicki is currently 72 years old. There are 7 older executives and no younger executives at Mereo BioPharma Group. Learn More on John A. Lewicki's age.
How do I contact John A. Lewicki?: The corporate mailing address for Lewicki and other Mereo BioPharma Group executives is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. Mereo BioPharma Group can also be reached via phone at 44-33-3023-7300 and via email at [email protected]. Learn More on John A. Lewicki's contact information.
Has John A. Lewicki been buying or selling shares of Mereo BioPharma Group?: John A. Lewicki has not been actively trading shares of Mereo BioPharma Group within the last three months. Most recently, John A. Lewicki sold 5,212 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a transaction totalling $23,297.64. Following the completion of the sale, the insider now directly owns 89,567 shares of the company's stock, valued at $400,364.49. Learn More on John A. Lewicki's trading history.
Who are Mereo BioPharma Group's active insiders?: Mereo BioPharma Group's insider roster includes Christine Fox (CFO), Alexandra Hughes-Wilson (Insider), John Lewicki (Insider), Deepika Pakianathan (Director), Denise Scots-Knight (CEO), and Charles Sermon (General Counsel). Learn More on Mereo BioPharma Group's active insiders.

John A. Lewicki Insider Trading History at Mereo BioPharma Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/12/2024	Sell	5,212	$4.47	$23,297.64	89,567
6/25/2024	Sell	7,416	$3.69	$27,365.04	65,587

John A. Lewicki Buying and Selling Activity at Mereo BioPharma Group

Mereo BioPharma Group Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $2.04

$1.90

$2.06

50 Day Range

MA: $1.92

$1.75

$2.24

2 Week Range

Now: $2.04

$1.47

$3.94

Volume

2,428,717 shs

Average Volume

1,837,555 shs

Market Capitalization

$324.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44